Infusion
Dexmedetomidinum
Dexmedetomidine Altan contains the active substance dexmedetomidine, which belongs to the group of sedative medicines. The medicine is used to provide sedation (a state of calm, sleepiness or sleep) in adult patients in the intensive care unit in the hospital or during various diagnostic procedures and surgical operations with preserved consciousness.
Before administering this medicine, tell your doctor or nurse if any of the following apply to you, as Dexmedetomidine Altan should be used with caution:
medicines, especially anesthetics. This medicine may cause excessive urine production and increased thirst. If such symptoms occur, you should contact your doctor. For further information, see section 4.
There is an increased risk of death in patients aged 65 and under who have been given this medicine, especially in patients admitted to the intensive care unit in a severe condition and for reasons other than post-operative care and at a younger age.
Your doctor will decide whether this medicine is still suitable for you. Your doctor will weigh the benefits and risks of using this medicine compared to other sedative medicines.
Tell your doctor or nurse about all medicines you are taking or have recently taken, as well as any medicines you plan to take.
The following medicines may enhance the effect of Dexmedetomidine Altan:
If you are taking medicines that lower blood pressure and slow heart rate, using Dexmedetomidine Altan at the same time may enhance this effect. Dexmedetomidine Altan should not be used with medicines that cause periodic paralysis.
Dexmedetomidine Altan should not be used during pregnancy or breastfeeding unless absolutely necessary.
Before using this medicine, consult your doctor or pharmacist.
Dexmedetomidine Altan has a major impact on the ability to drive and use machines. After receiving Dexmedetomidine Altan, you should not drive, operate machinery, or work in hazardous conditions. Ask your doctor when you can resume these activities.
This medicine contains less than 1 mmol (23 mg) of sodium per 2 ml ampoule and 4 ml vial, i.e. the medicine is considered "sodium-free".
The medicine contains 37 mg of sodium (the main component of common salt) in each 10 ml vial.
This corresponds to 2% of the maximum recommended daily intake of sodium in the diet for adults.
Dexmedetomidine Altan is administered to the patient by a doctor or nurse in the intensive care unit.
Dexmedetomidine Altan is administered to the patient by a doctor or nurse before or during diagnostic procedures or surgical operations that require sedation, so-called procedural sedation/analgesia with preserved consciousness.
The doctor will determine the dose suitable for the patient. The dose of Dexmedetomidine Altan depends on the patient's age, sex, overall health, and the required level of sedation, as well as the patient's response to the medicine.
The doctor may adjust the dose of the medicine if necessary and will monitor the patient's heart rate and blood pressure during treatment.
Dexmedetomidine Altan is diluted and administered to the patient intravenously in the form of an infusion (drip).
The doctor will monitor the patient for several hours after sedation to ensure that the patient feels well.
The patient should not return home alone.
For some time after receiving Dexmedetomidine Altan, you should not take medicines that facilitate sleep, cause sedation, or strong painkillers.
Talk to your doctor about taking these medicines and using alcohol.
If the patient has received too much Dexmedetomidine Altan, it may cause a decrease or increase in blood pressure, slowing of the heart rate, slower breathing, and a feeling of sleepiness.
The doctor knows how to treat the patient according to their condition.
If you have any further questions about the use of this medicine, ask your doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very common (more than 1 in 10 patients)
Common (between 1 and 10 patients in 100)
Uncommon (between 1 and 10 patients in 1000)
Rare (cannot be estimated from the available data)
If you experience any side effects, including those not listed in this package leaflet, tell your doctor or nurse. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
PL-02 222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
By reporting side effects, you can help provide more information on the safety of this medicine.
Side effects can also be reported to the marketing authorization holder.
Keep the medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the label and carton after "Expiry Date". The expiry date refers to the last day of the month.
There are no special storage precautions for the medicine. Store the ampoules or vials in the outer packaging to protect from light.
The active substance is dexmedetomidine. Each ml of concentrate contains dexmedetomidine hydrochloride equivalent to 100 micrograms of dexmedetomidine.
The medicine also contains sodium chloride, sodium hydroxide (for pH adjustment), hydrochloric acid (for pH adjustment), and water for injections.
Each 2 ml ampoule contains 200 micrograms of dexmedetomidine (as hydrochloride).
Each 4 ml vial contains 400 micrograms of dexmedetomidine (as hydrochloride).
Each 10 ml vial contains 1000 micrograms of dexmedetomidine (as hydrochloride).
The concentration of the ready-to-use solution after dilution should be 4 micrograms/ml or 8 micrograms/ml.
Concentrate for solution for infusion (sterile concentrate). The concentrate is a clear, colorless solution.
Containers:
glass ampoules of 2 ml capacity
glass vials of 6 or 10 ml capacity
Pack sizes
5 ampoules x 2 ml
25 ampoules x 2 ml
4 vials x 4 ml
4 vials x 10 ml
Not all pack sizes may be marketed.
Altan Pharma Ltd
The Lennox Building
50 South Richmond Street
Dublin 2
D02 FK02,
Ireland
Altan Pharmaceuticals, S.A.
Avda. De la Constitución 198-199
Polígono Industrial Monte Boyal
45950 Casarrubios del Monte (Toledo)
Spain
Altan Pharmaceuticals, S.A.
Polígono Industrial de Bernedo
s/n, Bernedo
01118 Álava
Spain
Detailed information on this medicine is available on the website of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products (http://www.urpl.gov.pl)
--------------------------------------------------------------------------------------------------------------
Information intended for healthcare professionals only:
Method of administration
Dexmedetomidine Altan should be administered by healthcare professionals specialized in the treatment of patients requiring intensive care or anesthesiological care in the operating room or during diagnostic procedures.
Dexmedetomidine Altan may only be administered as a diluted intravenous infusion using a controlled infusion set.
Preparation of the solution
To achieve the desired concentration of 4 micrograms/ml or 8 micrograms/ml, Dexmedetomidine Altan should be diluted before administration in a glucose 50 mg/ml (5%) solution, Ringer's solution, mannitol, or sodium chloride 9 mg/ml (0.9%) solution for injection.
The volumes required to prepare the infusion are given in the following table.
Volume of Dexmedetomidine Altan 100 micrograms/ml concentrate for solution for infusion | Volume of diluent | Total volume of infusion |
2 ml | 48 ml | 50 ml |
4 ml | 96 ml | 100 ml |
10 ml | 240 ml | 250 ml |
20 ml | 480 ml | 500 ml |
Volume of Dexmedetomidine Altan 100 micrograms/ml concentrate for solution for infusion | Volume of diluent | Total volume of infusion |
4 ml | 46 ml | 50 ml |
8 ml | 92 ml | 100 ml |
20 ml | 230 ml | 250 ml |
40 ml | 460 ml | 500 ml |
Gently shake the solution to ensure thorough mixing.
Before administration, Dexmedetomidine Altan should be visually inspected for particulate matter and discoloration.
It has been demonstrated that dexmedetomidine is compatible when administered with the following intravenous solutions and medicinal products:
Ringer's solution, 5% glucose solution, sodium chloride 9 mg/ml (0.9%) solution for injection, mannitol 200 mg/ml (20%), dexamethasone 4 mg, magnesium sulfate 10 mg/kg and 40 mg/kg, sufentanil 10 mcg/ml.
After dilution:
The chemical and physical stability of the diluted infusion (Stability of the diluted infusion) has been demonstrated for 24 hours at 25°C and under refrigeration (2°C – 8 °C).
From a microbiological point of view, the product should be used immediately. If the medicine is not used immediately, the user is responsible for the subsequent storage conditions and storage time before use.
The storage time should not normally exceed 24 hours at 2-8°C, unless the dilution has been performed under controlled and validated aseptic conditions.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.